NCT06828328View on ClinicalTrials.gov

A Study of Gene-edited GC203 TIL on the Pancreatic Ductal Adenocarcinoma

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 10, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2028

Conditions
Pancreatic CancerPancratic Ductal AdenocarcinomaTreatment Side EffectsTumor Infiltrating Lymphocytes
Interventions
BIOLOGICAL

GC203 TIL

the candidates will be assigned to GC203 TIL(gene-edited TIL) group

Trial Locations (1)

Unknown

RECRUITING

Ruijin Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Juncell Therapeutics

INDUSTRY